FDA Approved Drug for Emissions; Vets See Bloat Deaths, Lameness as Sales Top $200M

More than half the cattle in U.S. feedlots now eat a drug the FDA approved to cut ammonia emissions, not to boost growth.

Experior generated more than $200 million in sales in 2025 alone, and veterinarians in the field are seeing the same bloat deaths and lameness that showed up in the pre-approval studies.

The drug’s active ingredient, lubabegron, belongs to a class of growth-promoting pharmaceuticals banned or restricted in more than 160 countries over human safety concerns. Elanco Animal Health did not seek approval as a growth promoter.

Instead, the Indiana company pitched Experior as an environmental fix for feedlot ammonia. The FDA signed off in 2018 after Elanco showed that the drug could moderately reduce ammonia emissions from cattle — a gas that faces no federal or state emission limits on feedlots.

“The company used the FDA’s naivety,” one former Center for Veterinary Medicine scientist told Investigate Midwest. “Some people saw where this was going, but not everybody. So now we ended up with a drug that was not tested for growth being sold or being advertised as a drug for growth.”

Lameness and bloat appeared before approval

Across six studies Elanco submitted, cattle receiving the highest doses developed lameness more often than control groups. In two studies, researchers diagnosed bloat — a rapid buildup of gas in the rumen that can suffocate an animal — only in Experior-fed cattle. Most of those cases were discovered after the animals were found dead. Control groups recorded zero bloat cases.

One of the largest feedlots in the country is located in Nebraska near the Colorado and Kansas border
Photo: wsiu.org

The FDA attributed the lameness to muddy pens and diet, saying it improved with medicated foot baths. “This is scientifically not valid,” a former FDA scientist told Investigate Midwest. “It doesn’t mean that it didn’t happen or that it’s not due to the drug.” On bloat, the agency said the total number of cases was too low for meaningful statistical comparison.

Real-world reports mirror the trial signals

Feedlot veterinarians are reporting issues seen in the studies — bloat-related deaths, lameness and other complications — in connection with Experior use. Many reports mention bloat and respiratory disorders alongside the deaths; more than a dozen cite lameness and cattle unable to stand.

Elanco stands by the product. “Experior’s safety profile is documented and demonstrated through nearly two decades of required scientific studies,” communications representative Season Solario wrote in an email to Investigate Midwest. “Elanco remains fully confident in the safety and efficacy of Experior.”

Heavier carcasses, more animals arriving dead or down

Experior is one of several tools the industry uses to make cattle — and profits – bigger. Cheap corn makes longer feeding periods economical, and the spread of beef-on-dairy crossbreeding produces larger calves.

USDA slaughter data for 2017 through 2025 show that the number of cattle arriving at slaughterhouses dead or unable to stand increased among heifers and steers in 2024 and 2025. Compared with 2017, 44% more cattle arrived unable to stand and 36% more arrived dead — even though about 1.5 million fewer heifers and steers were slaughtered in 2025.

“There is currently no way to know whether consumers who eat beef with lubabegron residues will be affected,” wrote Dr. John Tegzes, citing flaws in the research that Elanco relied on to determine human safety, including outdated studies and small sample sizes. Tegzes warned that Experior’s effects on the heart and airways could pose a risk to people who consume beef.

The Experior label warns that individuals with cardiovascular disease should exercise special caution to avoid exposure. The Animal Legal Defense Fund sued the FDA in 2020, arguing the agency lacked sufficient information to determine the drug is safe for animals and consumers.

FDA Approved Drug for Emissions; Vets See Bloat Deaths, Lameness as Sales Top $200M
Photo: mdjonline.com

Academics tied to Elanco drove Experior success

Investigate Midwest found that academics with close ties to Elanco helped drive Experior’s commercial success. The FDA told Investigate Midwest that its role is ensuring the safety and effectiveness of new animal drugs.

The studies Elanco submitted were conducted in small closed pens and environmentally controlled chambers, not in the sprawling open-air feedlots. The FDA acknowledges the environmental benefits in real-world feedlots are unknown.